个人简历

工作经历\r
2011.6—2014.2江苏先声药业有限公司，项目经理\r
2014.2—2017.10西安交通大学药学院，讲师\r
2015年7月起 西安交通大学药学院，硕士生导师\r
2016.8—2017.8美国佐治亚州立大学, 访问学者\r
2017.11—至今西安交通大学药学院，副教授\r
\r
教育经历\r
2002.9—2006.6中国药科大学， 制药工程（本科）\r
2006.9—2011.6中国药科大学， 药物化学（博士）

研究领域

"""""（1）新药分子的发现与开发研究\r
（2）药物合成新技术与新工艺研究\r
（3）具有生物活性的有机小分子的设计与合成研究"

近期论文

Hao Lei, Shu Fan, Hao Zhang, Yan-Jie Liu, Yuan-Yuan Hei, Jun-Jie Zhang, A-Qun Zheng, Minhang Xin*, San-Qi Zhang*, Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors, European Journal of Medicinal Chemistry, 2020, 186, 111888.\r
\r
Hong-Yi Zhao, Xue-Yan Yang, Hao Lei, Xiao-Xiao Xi, She-Min Lu, Jun-Jie Zhang, Minhang Xin*, San-Qi Zhang*, Discovery of potent small molecule PROTACs targeting mutant EGFR. European Journal of Medicinal Chemistry, 2020. 208, 112781.\r
\r
Jiajia Sun, Yifan Feng, Yuan Huang, San-Qi Zhang, Minhang Xin*, Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors, Bioorganic Medicinal Chemistry Letters, 2020, 30(19), 127457.\r
\r
Minhang Xin*, Jiajia Sun, Wei Huang*, Feng Tang, Zhaoyu Liu, Qiu Jin, Jia Wang, Design and synthesis of novel phpyridazinone derivatives as potent poly(ADP-ribose)polymerase (PARP) inhibitors, Future Medicinal Chemistry, 2020,12(19), 1691-1707.\r
\r
Minhang Xin*, Xinyue Ji, Ladie Kimberly De La Cruz, Suresh Thareja, Binghe Wang*, Strategies to target the Hedgehog signaling pathway for cancer therapy, Medicinal Research Reviews, 2018, 38(3): 870-913.